Everything we do starts with our Mission: to enable our customers to make the world healthier, cleaner, and safer. The nature of our business is to enable growth and innovation within the global scientific community and to help researchers, organizations, and companies solve some of the world’s most pressing issues. We do that by providing cutting-edge technologies and services that are the result of our significant investment in research and development. We believe creating a better tomorrow starts with the action we take today, and we continually strive toward improvement and excellence for the benefit of our customers, our colleagues, and the world.
Great strides have been made over the last two decades in cancer research thanks in part to technology such as next-generation sequencing (NGS). The amount of genomic data generated as a result of faster and more robust NGS platforms has helped lead to a better understanding of cancer, and this information is advancing the development of therapies that are helping to prolong the lives of many cancer survivors.
Despite these advances, the vast majority of patients are not yet benefiting from them because the technology that can help match them more quickly to potentially more effective therapies is generally not yet available in community hospitals, where most patients are diagnosed and treated.
Thermo Fisher took a major step toward providing increased access to genomic testing through the introduction of the Ion Torrent Genexus System in 2019. The NGS platform is the first system of its kind that is able to generate a comprehensive genomic profile in a single day. It is also designed with an automated, simple-to-use workflow that virtually any properly-certified hospital lab can adopt, and can return a comprehensive genomic report using minimal amounts of sample.